Archives
-
Barley Leaf Senescence and Cathepsin B/L Proteases
2026-08-28
Schepetkin and Fischer combined activity-based assays, inhibitor profiling, DCG-04 labeling, and immunoblotting to characterize cysteine proteases during barley leaf senescence. Their results show that cathepsin L-like activity is prominent, while cathepsin B-like proteases and senescence-associated markers also increase, providing a biochemical framework for studying proteolytic nutrient remobilization.
-
15-PGDH Inhibition Preserves Muscle During Weight Loss
2026-08-28
A 2026 PNAS study identifies 15-PGDH inhibition as a strategy to improve skeletal muscle regeneration and force recovery during semaglutide-associated weight loss in obese mice. The work shows that a 15-PGDH inhibitor can enhance muscle stem cell activity and regenerated myofiber growth without reducing semaglutide’s weight-loss effect.
-
AMG 487: Rethinking CXCR3 in Macrophage State
2026-08-27
AMG 487 is more than a conventional CXCR3 antagonist: it is a mechanistic probe for understanding how chemokine signaling, autophagy, and macrophage state interact. Evidence from a 2024 study suggests that CXCR3 blockade can produce opposite polarization outcomes depending on inflammatory context, creating a valuable translational framework for assay design and interpretation.
-
Bufalin Targets STK33 in Triple-Negative Breast Cancer
2026-08-27
The 2025 Advanced Science study identifies Serine/Threonine Kinase 33 (STK33) as a direct binding target and degradation-sensitive mediator of Bufalin activity in triple-negative breast cancer. By combining proteomic target discovery, biophysical validation, genetic perturbation, animal models, and patient-derived organoids, the authors connect STK33 loss to disruption of the STK33–HSP90–CCAR1 axis.
-
Cefodizime Workflows for Antibacterial Assays
2026-08-26
Build reproducible Cefodizime assays around PBP-directed killing, organism-specific controls, and matrix-aware MIC testing. This workflow also shows how to evaluate respiratory and urinary pathogens while avoiding predictable failures involving precipitation, inoculum drift, and resistant phenotypes.
-
Escitalopram Workflows for Serotonin Research
2026-08-26
Build reproducible SERT uptake, binding, and serotonergic signaling assays with Escitalopram, while using clinical stratification concepts to sharpen translational study design. Practical dosing, controls, and troubleshooting guidance help distinguish genuine 5-HT reuptake inhibition from formulation, timing, or assay artifacts.
-
Caspase-3 Colorimetric Assay Kit: ER Stress Insight
2026-08-25
A translational framework for connecting ER-stress biology in intestinal macrophages with functional caspase-3 activity measurement, using the Caspase-3 Colorimetric Assay Kit as a practical validation tool rather than treating apoptosis as an assumed endpoint.
-
nor-NOHA Acetate: Arginase Workflows
2026-08-25
Build reproducible arginine-metabolism experiments with nor-NOHA acetate, from enzyme validation and HepG2 phenotyping to endothelial readouts. The workflow also shows how to test arginase biology alongside the CD36-driven immune-escape program reported in AML without overstating evidence.
-
Paroxetine Mesylate Beyond the SSRI Label
2026-08-24
Paroxetine Mesylate is best understood as a pharmacology platform rather than a single-purpose antidepressant. This thought-leadership guide connects SERT biology with CYP2D6, GRK2, MET, and ERBB3 evidence to help translational researchers design more discriminating assays, interpret colorectal cancer findings, and avoid overextending early mechanistic signals.
-
Capsaicin as a KDM1A/LSD1 Inhibitor
2026-08-24
The reference study identifies Capsaicin, also called (E)-Capsaicin, as a direct, reversible, FAD-competitive inhibitor of lysine-specific demethylase 1A (KDM1A/LSD1). Its biochemical activity and effects on BGC-823 gastric cancer cells connect a familiar TRPV1-active natural product with histone methylation, EMT, and cancer-cell invasion research, while also highlighting important limits for translation.
-
SW033291: 15-PGDH Inhibitor Workflows
2026-08-23
SW033291 is a nanomolar 15-PGDH inhibitor for testing how endogenous prostaglandin E2 elevation influences hematopoiesis, tissue repair, and muscle regeneration. This workflow-focused guide connects biochemical target engagement with cell-based readouts and the emerging muscle-repair application identified during GLP-1 receptor agonist–associated weight loss.
-
Lapatinib Beyond HER2: A Translational Playbook
2026-08-22
Lapatinib, also known as GW572016, offers translational researchers a controllable way to connect EGFR and HER2 kinase inhibition with cell-cycle, proliferation, invasion, and angiogenesis phenotypes. This article outlines how to interpret its biochemical potency, design receptor-defined and phenotype-first assays, and extend HER2-associated cancer research without confusing target engagement with clinical efficacy.
-
Olsalazine Sodium: From Assay to Xenobiotic Insight
2026-08-22
Olsalazine Sodium is a mesalamine dimer with applications spanning inflammation research and colorectal cancer models. This article explains how its physicochemical behavior can guide xenobiotic-disposition assays without overinterpreting transporter expression data.
-
Saquinavir as a Membrane-Partitioning Benchmark
2026-08-21
Saquinavir is more than an HIV protease inhibitor: it can serve as a chemically defined probe for connecting antiviral mechanism with biomimetic membrane-partitioning assays. This guide translates recent IAM-LC and LEKC findings into practical assay-selection and interpretation strategies.
-
Hoechst 33342: From Nuclear Signal to HPH Insight
2026-08-20
Hoechst 33342 can do more than label nuclei: strategically deployed, it connects chromatin morphology, cell-cycle state, and apoptosis with the endothelial–smooth muscle communication implicated in hypoxia pulmonary hypertension. This article outlines how translational researchers can use a bis-benzimidazole fluorescent dye to strengthen mechanistic validation without mistaking a nuclear readout for pathway-specific proof.